TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05069129

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)
Description: Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine (Vero cells)
Description: Intramuscular injection of Inactivated COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine (Vero cells)
Description: Intramuscular injection of Inactivated COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine (Vero cells)
Description: Intramuscular injection of Inactivated COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 doses Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)
Description: Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm on 0，30，60 days
Study: NCT06198907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golidocitinib
Description: Daily dosing of golidocitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golidocitinib
Description: Daily dosing of golidocitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golidocitinib
Description: Daily dosing of golidocitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab, 200mg, intravenous, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab, 200mg, intravenous, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab, 200mg, intravenous, every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platinum doublet chemotherapy
Description: Pemetrexed or nab-paclitaxel +carboplatin, intravenous, every 3 weeks for 2 cycles
Study: NCT05228782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOW R U? Intervention
Description: HOW RU? intervention uses trained volunteer peers to provide strength-based support sessions weekly for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOW R U? Intervention
Description: HOW RU? intervention uses trained volunteer peers to provide strength-based support sessions weekly for 12 weeks.
Study: NCT06417086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. There will be 12 weeks of 3-session treatment for each participant in total.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Acupuncture
Description: The Streitberger placebo needle will be used to simulate an acupuncture procedure without penetrating the skin. The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. There will be 12 weeks of 3-session treatment for each participant in total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil 5 mg will be given once daily before bed-time for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Donepezil 5 mg will be given once daily before bed-time for 12 weeks.
Study: NCT06537661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Virtual reality (VR): is the artificial construction of a 3D environment viaThe VR glasses which were the source of visual and auditory feedback, were connected by Bluetooth to a mobile phone and all the videos of selected tasks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional exercises
Description: Active mobility exercises (jaw opening 6 times of 30 s; lateralization 10 times of 5 s; protrusion 10 times Of 5 s). Self-massage masticatory Muscles, After each session.~* Isometric contraction exercises Were included (3 times of 10 s)
Study: NCT06515665

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic foot orthosis
Description: They will be asked to behaviorally wear this shoe and perform the exercises daily for 6 weeks.
Study: NCT04647058

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cubital tunnel release
Description: The control group will undergo cubital tunnel release in situ. In cases of preoperative or intraoperative ulnar nerve instability, anterior transposition of the ulnar nerve will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supercharged end-to-side (SETS) nerve transfer
Description: The SETS group will undergo the same procedure as described above, with the addition of the SETS procedure consisting of a end-to-side transfer of the anterior interosseous nerve to the ulnar nerve motor branch. Decompression of Guyon's canal during the SETS procedure is at the discretion of the treating surgeon.
Study: NCT04699331

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial direct current stimulation is a form of noninvasive neuromodulation that uses constant and low direct current delivered via electrodes on the scalp.
Study: NCT05576116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy AND Pancreas after Kidney Transplantation (Staggered Approach)
Description: Participants will undergo sleeve gastrectomy a minimum of 3 months prior to Pancreas Transplant. SG will be performed using the standard technique.~Pancreas transplant will be performed as per standard procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Sleeve Gastrectomy and Pancreas transplantation
Description: Simultaneous SG and pancreas transplantation
Study: NCT06202638

Intervention type: DEVICE
Intervention: HemoSphere monitor with Acumen Hypotension Prediction Index Software
Description: Two concomitant courses of intraoperative data will be recorded: 1. the arterial waveform and pressure on the standard hemodynamic patient monitor and 2. the data from the HemoSphere monitor with Acumen Hypotension Prediction Index Software
Study: NCT05287191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate and then Digoxin
Description: We will test MgSO4 and then digoxin IV (in 3 divided dose) as second line therapy with amiodarone IV as third line. Digoxin will be protocolised to commence between 30 minutes and 12 hours after MgSO4 if fast Atrial Fibrillation persists as initially designated (dose 1). Undiluted IV digoxin (12 mcg/kg) will be administered in 3 divided doses (6, 3 and 3 mcg/kg) separated by approximately 6 hrs (i.e. dose 1 at 30 mins - 12 hours after MgSO4, followed by dose 2 at -6 hrs and dose 3 at the approximately 12 hrs). Patients with renal dysfunction (creatinine clearance \<60 ml/min measured by the Modification of diet in renal disease formula) will receive a reduced dose of 8 mcg/kg in 3 divided doses (4, 2, and 2 mcg/kg) separated by the same time intervals. In the trial intervention group, amiodarone will be given approximately 120 mins after digoxin if necessary whilst completing the digoxin dose. Amiodarone as a 150 mg infusion over 10 minutes followed by 900 mg over 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: We will test Amiodarone (150mg IV then 900mg IV over the next 24 hours ) as first line treatment in the standard of care group. No more than 2g MgSO4 be delivered over 2 hours maximum for this group in the first 24 hours after randomisation unless clinically indicated for measured hypomagnesaemia (a value below the index hospital laboratories lower limit of normal).
Study: NCT04672005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox alternating with Gemcitabine-nab-Paclitaxel
Description: modified Folfirinox every 2 weeks and biweekly Gemcitabine plus Nab-Paclitaxel
Study: NCT05562232

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: Follows

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Creatine Monohydrate
Description: Follows
Study: NCT05685797

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: trigminal nerve block with RFT
Description: trigminal nerve block with RFT
Study: NCT05472259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nanoliposomal irinotecan
Description: In the control arm (Naliri) a dose of 70mg/m² is administered in combination with 5FU and leucovorin In the investigational arm (Nalirinox) a dose of 50mg/m² is administered in combination with 5FU, leucovorin and oxaliplatin
Study: NCT05334524

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesiotaping with combined chain exercises
Description: 3 Kinesiotape strips will be applied: 2 Y-strips with a length of approximately 20 cm and an anchor of 2 cm and a single longitudinal section (1 I-strip). Tails of the quadriceps strip were applied to the patella, wrapping the patella medially and laterally with 25% tension and the (I-strip) will be applied with 75% tension.~Combined chain exercises will apply with 10 secs hold with 10 repetitions which will include quadriceps setting, SLR, full arc extension, cycling in the air, wall slides and step-up and step-down exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesiotaping
Description: 3 Kinesiotape strips will be applied: 2 Y-strips with a length of approximately 20 cm and an anchor of 2 cm and a single longitudinal section (1 I-strip). Tails of the quadriceps strip were applied to the patella, wrapping the patella medially and laterally with 25% tension and the (I-strip) will be applied with 75% tension

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesiotaping
Description: 3 Kinesiotape strips will be applied: 2 Y-strips with a length of approximately 20 cm and an anchor of 2 cm and a single longitudinal section (1 I-strip). Tails of the quadriceps strip were applied to the patella, wrapping the patella medially and laterally with 25% tension and the (I-strip) will be applied with 75% tension
Study: NCT06262763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Therapy
Description: High-intensity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional exercises
Description: Hamstring and piriformis stretch, plank exercises and bird dog exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Traditional exercises
Description: Hamstring and piriformis stretch, plank exercises and bird dog exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo laser
Description: Not directed radiation to participant
Study: NCT00944060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Study: NCT05472259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal irinotecan
Description: In the control arm (Naliri) a dose of 70mg/m² is administered in combination with 5FU and leucovorin In the investigational arm (Nalirinox) a dose of 50mg/m² is administered in combination with 5FU, leucovorin and oxaliplatin
Study: NCT05021900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenalisib 800mg
Description: Tenalisib will be administered 800mg BID, orally
Study: NCT05472259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 FU
Description: In the control arm (Naliri) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan and leucovorin In the investigational arm (Nalirinox) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan, leucovorin and oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 FU
Description: In the control arm (Naliri) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan and leucovorin In the investigational arm (Nalirinox) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan, leucovorin and oxaliplatin
Study: NCT05021900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenalisib 1200mg
Description: Tenalisib will be administered 1200mg BID, orally
Study: NCT05527301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus Fermentum
Description: Lactobacillus Fermentum

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05198414

Intervention type: OTHER
Intervention: Focus group
Description: Qualitative research methodology with healthcare workers
Study: NCT05252273

Intervention type: OTHER
Intervention: Observational, No intervention
Description: Open-label observational study that will evaluate the reliability and responsiveness of patient-reported symptoms and endoscopic and histologic items for assessing pouchitis disease activity in 43 patients undergoing standard of care (SOC) antibiotic therapy.
Study: NCT06565897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test regimen
Description: toothpaste \& manual toothbrush

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control regimen
Description: toothpaste \& manual toothbrush
Study: NCT04766970

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ADOS-2 Module 4
Description: Assessment in person using standardized Autism Diagnostic Observation Schedule, 2nd Edition (ADOS-2) Module 4.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Telehealth ADOS-2 Module 4
Description: Assessment via telehealth/teleconference platform using an adapted ADOS-2, Module 4 assessment protocol.
Study: NCT05219513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7443904
Description: RO7443904 will be administered by subcutaneous (SC) or IV infusion on Cycle (C) 1 Day (D) 10, C2D3, and C2D8. From C3 onward, RO7443904 will be given every 3 weeks (Q3W), for up to 12 cycles (C = 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7443904
Description: RO7443904 will be administered by subcutaneous (SC) or IV infusion on Cycle (C) 1 Day (D) 10, C2D3, and C2D8. From C3 onward, RO7443904 will be given every 3 weeks (Q3W), for up to 12 cycles (C = 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab will be administered through IV infusion starting with step-up dosing (2.5 mg/10 mg/30 mg) on C1D1, C1D8, and C2D1. Starting in Cycle 3, glofitamab will be given in 30 mg doses every three weeks (Q3W) with RO7443904, for up to 12 cycles (Cycle = 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab will be administered through IV infusion starting with step-up dosing (2.5 mg/10 mg/30 mg) on C1D1, C1D8, and C2D1. Starting in Cycle 3, glofitamab will be given in 30 mg doses every three weeks (Q3W) with RO7443904, for up to 12 cycles (Cycle = 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered once through IV infusion, at a 1 g dose in Cycle 1, on either Day -7, -4, or -3 (C1D-7, C1D-4, C1D-3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
Study: NCT04779242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: IV for injection, oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: IV solution, oral tablets
Study: NCT04387487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimedia video information
Description: During pre anesthesia visit after regular pre anesthesia check up patient will be asked to fill the Hamilton scoring questionnaire about anxiety.~After this a multimedia video information about spinal anesthesia of around 6 minutes will be shown to the intervention group during pre anesthesia visit. This video will contain explanation about how spinal anesthesia procedure is conducted. Patient will be allowed to ask questions.~On the day of surgery in the pre surgical area again Hamilton scoring questionnaire will be asked with the patients to check the level of anxiety.
Study: NCT05472259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: In the control arm (Naliri) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan and 5FU In the investigational arm (Nalirinox) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: In the control arm (Naliri) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan and 5FU In the investigational arm (Nalirinox) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and oxaliplatin
Study: NCT05686928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetaphil Healing Ointment
Description: Topical ointment application twice daily
Study: NCT04891445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing monitoring program
Description: A clinical pathway will be activate that allows all the necessary interventions, once the person is diagnosed, to be carried out on the same day, and a mental health nursing team will monitor the entire process.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: As usual
Description: Referral to the family doctor for a request for follow-up by the gastroenterologist. The specialist prescribes the tests for the definitive diagnosis that will take place in other units (with their corresponding appointments). After this, the patient will return to the specialist to establish the treatment to follow. Pharmacological treatment will be dispensed at the hospital pharmacy (collected once a month until completion of treatment and confirmation of cure). This last step of the treatment will be done in a new consultation at the gastroenterology service after blood tests to verify the disappearance of the viral load.
Study: NCT06467292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta-burst stimulation (cTBS)
Description: cTBS stimulation will be applied to different areas of the brain following learning. Stimulation will take place following learning in order to block motor memory retention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Auditory adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Auditory adaptation in speech

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptation
Description: Auditory adaptation in speech

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single pulse Transcranial magnetic stimulation (TMS)
Description: TMS will be delivered 10 times in each motor evoked potentials (MEP) recording block.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: To assess functional connectivity patterns between regions that predict learning.
Study: NCT05948826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORL-3-600
Description: antibody drug conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORL-3-600
Description: antibody drug conjugate
Study: NCT06491433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H2-BP
Description: The patient will have the test device applied to one wrist to measure blood pressure and the control device applied to the upper arm of the same arm to measure blood pressure.~1. H2-BP: The test device is placed on the wrist and presses a button to start pressurising. When the measurement is complete, the systolic and diastolic blood pressure is displayed on the screen.~2. big ben® Sphygmomanometer: The cuff is placed on the upper arm and the pump is pressed manually to inflate. 2 measurers will measure systolic and diastolic blood pressure by connecting 2 stethoscopes separately to one cuff.~Due to the external nature of the study medical device, it is not possible to blind subjects and investigators, so that subjects and measurers are aware of the allocation. Therefore, blinding of subjects and measurers will not be used in this study.
Study: NCT05797142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses
Description: Beginning 1-2 minute before the start of the procedure, the patients will be watched (30 minutes) with an android mobile phone inserted into the Cardboard Super Flex Binoculars Glasses, with a music background, licensed product Secret Garden, during the procedure (30 minutes).
Study: NCT05518409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Detection of cytof in peripheral PBMC
Description: Each subject needs to take 5ml of peripheral venous blood to extract PBMC cells, and then conduct cytof detection. This is a mass spectrometry flow cytometry method based on single cell level. It has the ability to analyze all immune cells with high resolution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Detection of cytof in peripheral PBMC
Description: Each subject needs to take 5ml of peripheral venous blood to extract PBMC cells, and then conduct cytof detection. This is a mass spectrometry flow cytometry method based on single cell level. It has the ability to analyze all immune cells with high resolution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Detection of cytof in peripheral PBMC
Description: Each subject needs to take 5ml of peripheral venous blood to extract PBMC cells, and then conduct cytof detection. This is a mass spectrometry flow cytometry method based on single cell level. It has the ability to analyze all immune cells with high resolution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil for patients with AD and DLB
Description: The subjects in AD and DLB groups were given donepezil at an initial dose of 5mg and then increased to 10mg one month later. Lasting for 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil for patients with AD and DLB
Description: The subjects in AD and DLB groups were given donepezil at an initial dose of 5mg and then increased to 10mg one month later. Lasting for 1 year.
Study: NCT05327803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epetraborole
Description: 500 mg taken orally QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken orally QD